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Abstract
Background: Muscle weakness is associated with a variety of chronic disorders such as emphysema (EMP) and
congestive heart failure (CHF) as well as aging. Therapies to treat muscle weakness associated with chronic disease
or aging are lacking. Corticotrophin releasing factor 2 receptor (CRF2R) agonists have been shown to maintain
skeletal muscle mass and force production in a variety of acute conditions that lead to skeletal muscle wasting.
Hypothesis: We hypothesize that treating animals with a CRF2R agonist will maintain skeletal muscle mass and
force production in animals with chronic disease and in aged animals.
Methods: We utilized animal models of aging, CHF and EMP to evaluate the potential of CRF2R agonist treatment
to maintain skeletal muscle mass and force production in aged animals and animals with CHF and EMP.
Results: In aged rats, we demonstrate that treatment with a CRF2R agonist for up to 3 months results in greater
extensor digitorum longus (EDL) force production, EDL mass, soleus mass and soleus force production compared
to age matched untreated animals. In the hamster EMP model, we demonstrate that treatment with a CRF2R
agonist for up to 5 months results in greater EDL force production in EMP hamsters when compared to vehicle
treated EMP hamsters and greater EDL mass and force in normal hamsters when compared to vehicle treated
normal hamsters. In the rat CHF model, we demonstrate that treatment with a CRF2R agonist for up to 3 months
results in greater EDL and soleus muscle mass and force production in CHF rats and normal rats when compared
to the corresponding vehicle treated animals.
Conclusions: These data demonstrate that the underlying physiological conditions associated with chronic
diseases such as CHF and emphysema in addition to aging do not reduce the potential of CRF2R agonists to
maintain skeletal muscle mass and force production.
Background
Aging and frailty
Skeletal muscle mass and function is reduced during
aging resulting in frailty and weakness in elderly indivi-
duals, thereby markedly increasing the risk of disability
and loss of functional capacity [1]. The loss of skeletal
muscle mass and function with aging results in
decreased reserves of skeletal muscle which, when com-
bined with acute illness, often results in decreased mobi-
lity and quality of life [1]. Current concepts regarding
the mechanisms that cause the loss of skeletal muscle
mass and function during aging include some combina-
tion of inactivity, nutritional imbalance, cumulative
damage, metabolic alterations resulting in increased cat-
abolism and decreased anabolism, hormone loss (includ-
ing growth hormone, IGF-1, androgens and estrogen), * Correspondence: isfort.rj@pg.com
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cle regeneration potential [2-8].
A n i m a l sa sw e l la sh u m a n ss u f f e rf r o ma g i n gr e l a t e d
loss of skeletal muscle function. Several animal models
of aging related muscle loss exist, with one of the most
studied models being the 24 month old aging rat model
[9-15]. Aging F344 rats demonstrate many of the hall-
marks of human aging related muscle loss and have
been used to evaluate the potential of several com-
pounds, including beta adrenergic agonists and ACE
inhibitors, to prevent or reverse aging related muscle
loss [10,12-14,16-19].
Emphysema and Muscle Function
Chronic hypercapnia is associated with a poor prognosis
in patients afflicted with chronic obstructive pulmonary
disease (COPD) [20,21]. The mechanisms leading to
chronic hypercapnia are not fully known although it is
believed that inspiratory muscle fatigue and/or weakness
leads to CO2 retention and ultimately respiratory failure.
Indeed, Roussos demonstrated that hypercapnic COPD
patients reach a critical zone of fatigue by requiring 2-3
times the transdiaphragmatic pressure that normocapnic
patients produce during breathing at rest [22]. In COPD
patients, respiratory muscle weakness and diaphragm
fiber atrophy decreases respiratory muscle reserves
increasing muscle fatigability/weakness thereby predis-
posing the patient to chronic hypercapnia [23]. The
changes in diaphragm muscle that occur during EMP
include muscle fiber shortening by loss of sarcomeres in
series [24,25], increase in cross-sectional area of type I
and II fibers [26,27], atrophy [28,29] and loss of oxida-
tive enzyme capacity [30]. While the adaptive changes in
diaphragm muscle are complex, ultimately EMP aug-
ments the energetic requirements of respiratory muscles
which, concomitant with EMP-induced reductions in
muscle mass, contributes to diaphragm weakness,
increased fatigability and overall dysfunction.
In EMP, the diaphragm is not the only skeletal muscle
to develop weakness. In humans and animals with EMP,
changes in peripheral skeletal muscles have been
described including atrophy [27,31], reduced myocyte
cross-sectional area [27,31], loss of type IIB fibers [27],
increased fatigability [32,33], lipofuscin inclusions [33]
and increased antioxidant enzyme levels [33]. Thus in
EMP, overall skeletal muscle function is altered and
therapies with the potential to improve skeletal muscle
function may have beneficial effects.
CHF and muscle wasting
Skeletal muscle wasting associated with congestive heart
failure is part of a general wasting syndrome associated
with CHF known as cardiac cachexia [34]. Cardiac
cachexia typically affects about 20% of CHF patients
with the cachectic CHF patients showing reduced mus-
cle mass and strength resulting in reduced exercise
capacity and impaired activities of daily living when
compared to noncachectic CHF patients [34]. The
mechanism(s) responsible for CHF associated skeletal
muscle wasting are at present unknown although it has
been proposed that alterations in catabolic cytokines/
hormones such as TNF-a, IL-6 and cortisol result in
CHF mediate skeletal muscle wasting [34-36]. In order
to study CHF associated skeletal muscle wasting, rodent
CHF models have been extensively utilized with one of
the most relevant model being the experimental infarct
model [37-45]. Clinical and animal studies have demon-
strated that various pharmacological agents such as
human growth hormone, angiotensin II receptor antago-
nists and ghrelin can reduce the level of muscle wasting
associated with CHF [37-39]. Thus, pharmacologically-
induced increases in skeletal muscle mass and strength
in CHF patients with skeletal muscle wasting may
improve skeletal muscle strength and function.
CRF2R activation and muscle function
Recently, we have demonstrated that activation of the
CRF2R reduces acute skeletal muscle atrophy resulting
from disuse, nerve damage, corticosteroid treatment and
causes hypertrophy of non-atrophying skeletal muscle in
healthy animals [46-48]. CRF2R activation also reduces
skeletal muscle wasting associated with two chronic dis-
ease conditions, cancer and muscular dystrophy [49-51].
We have not yet investigated if activation of the CRF2R
will maintain skeletal muscle mass and force production
in animals that have an underlying chronic condition
that results in muscle wasting. Therefore, we have uti-
lized the aging rat model, the emphysematous hamster
model and the rat CHF model to determine if activation
of the CRF2R will maintain skeletal muscle mass and
force production in chronically ill and aged animals.
The results of these investigations are presented in this
report.
Methods
The CRF2R selective agonist PG873637 was synthesized
at Procter & Gamble as described previously [52].
Twenty eight day rat osmotic minipumps were pur-
chased from Alza Corporation (Palo Alto, CA).
PG873637 was administered using twenty eight day
osmotic minipumps at a dose of 100 ug/kg/d, which we
have shown provides maximal CRF2R agonist activity
over the 28 day dosing period (unpublished data). All
animal studies described in this report were conducted
in compliance with the US Animal Welfare Act, the
rules and regulations of the State of Ohio Departments
of Health, Procter & Gamble’s policy on research invol-
ving animals with strict oversight for care and welfare
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tional Animal Care and Use Committee. In addition, the
protocols used in the hamster emphysema studies were
approved by the Gustavus Adolphus College and the
Kansas State University Institutional Animal Care and
Use Committees. In all respects, they conform to the
Guide for the Care and Use of Laboratory Animals pub-
lished by the US National Institutes of Health (NIH
Publication No. 8523, revised 1985).
Aging rat model
Between 8 (time 0 and 1 month treatment) and 16 (3
months treatment) 24 month old F344 female rats per
treatment group, purchased from the Harlan (Indiana-
polis, IN), were double-housed and acclimatized to the
conditions of the facility for approximately 1 week
before use. Rats had access to lab chow and water ad
libitum and were subjected to standard conditions of
humidity, temperature and a 12 hour light cycle. Rats
were divided into five treatment groups: Time 0 - 24
months old rats prior to treatment; 1 month vehicle -
24 month old rats at initiation of treatment and treated
with vehicle for 1 month (25 months old at time of har-
vest); 1 month PG873637 - 24 month old rats at initia-
tion of treatment and treated with 100 ug/kg/day
PG873637 for 1 month (25 months old at time of har-
vest); 3 month vehicle - 24 month old rats at initiation
of treatment and treated with vehicle for 3 months (27
months old at time of harvest); 3 month PG873637 - 24
month old rats at initiation of treatment and treated
with 100 ug/kg/day PG873637 for 3 months (27 months
old at time of harvest). A larger number of rats were
included in the 3 month treatment group (compared to
time 0 and 1 month) since loss of rats due to their
extreme age was anticipated. Rats were anesthetized
with isoflurane and Alza 28-day rat minipumps contain-
ing either vehicle or PG873637 were implanted subcuta-
neously in the midscapular region of the back. Pumps
were replaced every 28 days until the end of the study.
At the specified times, rats were sacrificed and leg mus-
cles were removed and evaluated.
Hamster emphysema model
Male 3 month old Syrian Golden hamsters (120-130 g)
were purchased from Harlan (Indianapolis, IN) and
were housed using standard conditions including ad libi-
tum access to lab chow/water, standard conditions of
humidity/temperature and a 12 hour light cycle. Ham-
sters were divided randomly into sham (n =1 4 )a n d
emphysema (EMP) conditions (n = 24). Under deep
ketamine/xylazine anesthesia (150/7.5 mg/kg im), either
saline (0.3 ml/100 g body wt) (Sham) or porcine elastase
(25 IU/100 g body wt in 0.3 ml of normal saline, Sigma
Chemical, St. Louis, MO) (EMP) was instilled
intratracheally as described previously (Mattson and
Poole, 1998). Four months following instillation, ham-
sters were assigned randomly to the following experi-
mental groups: (6 Sham-Vehicle + 13 EMP-Vehicle) +
(6 Sham-Treatment + 12 EMP-Treatment). The CRF2R
selective agonist (PG873637) (Treatment) or physiologi-
cal saline (Vehicle) was delivered (100 μg/kg/d) via 28-
day osmotic mini-pumps implanted in the midscapular
region starting at month 4 and changed monthly for 5
months. Following 5 months of treatment, the lungs,
heart, costal diaphragm and EDL muscle were removed
and evaluated. To determine disease severity, a saline
displacement technique was used to measure excised
lung volume and the right ventricle (RV) was dissected
and weighed as described previously [53].
Rat CHF model
Myocardial infarction (MI) surgery
Surgically-induced myocardial infarctions were per-
formed as described previously [54]. Male 3 month old
Lewis rats were purchased from the Charles River
Laboratories and double-housed and acclimatized to the
conditions of the facility for approximately 1 week
before use. Rats had access to lab chow and water ad
libitum and were subjected to standard conditions of
humidity, temperature and a 12 hour light cycle. Rats
were administered an injection of an analgesic [bupre-
norphine, 0.05 mg/kg, intramuscular (im)] and an anti-
biotic (amoxicillin, 125 mg/kg, sc) prior to surgery. Rats
were then anesthetized with 2-5% isoflurane. Once
anesthetized, an endotracheal tube was placed in the
trachea of each rat and a respirator used to mechanically
ventilate the rat and control the flow of isoflurane. Next,
electrocardiogram (ECG) electrodes were attached and
the ECG monitored. Animals were then injected with
lidocaine 2% (0.1 ml/rat, im) to stabilize heart rhythm.
The surgical site was prepared by shaving the left thor-
acic area, disinfecting the skin with surgical scrub, and
wiping with 70% isopropanol. A left thoracotomy was
performed at the fifth intercostal space to the left of the
sternum, the heart carefully exposed, the pericardium
opened, and the left anterior descending coronary artery
(LAD) located. One or more 5-0 ligatures were perma-
nently tied around the LAD, and the heart replaced in
the chest. The heart rate and rhythm was monitored for
approximately 10 minutes, and supplemental lidocaine
administered as needed. Once cardiac rhythm stabilized,
the lungs were maximally inflated and the incision
closed with suture. Mechanical ventilation was discon-
tinued when the animal was able to breathe unassisted.
The endotracheal tube was removed when the animal
exhibited a swallow reflex. Animals were then allowed
to recover from anesthesia in heated cages and visually
monitored for signs of distress for approximately
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(0.05 mg/kg, im) daily for 2 days following surgery.
Echocardiography evaluation
Previously infarcted male Lewis rats were anesthetized
with isoflurane. The chest was shaved, and short-axis
and long-axis views of the left ventricle were captured.
Mitral and aortic Doppler flows were also taken to esti-
mate cardiac output and LV compliance. After the
examination, the animals were returned to their cages to
recover from anesthesia.
Infarct screening by echocardiography
Myocardial infarct size was determined by echocardio-
graphy. Approximately 1-2 weeks post-ligation, rats
were screened for infarct size. Rats were grouped based
on clinical presentation as follows: group 1 - small
infarct, scar area circumference of 25% or less and a
FAC < 30%; group 2 - medium to large infarct, scar area
circumference of >33%, FAC < 30%, mitral regurgitation
and LV dilation; group 3 - very large infarct, scar area
circumference of >40%, FAC < 30%. Rats were rando-
mized into treatment groups based on infarct size; only
rats having a large myocardial infarct (40% or greater)
were used that met the following inclusion criteria -
large scar, diastolic dilation and decreased fractional
area contraction (FAC) as follows. Sham surgery con-
sisted of the same surgery without ligation of the coron-
ary artery. Drug treatment (vehicle or active) was started
6 weeks post surgery for both myocardial infarcted and
sham surgery rats.
Post-mortem infarct analysis
The intact LV myocardium and scar were splayed,
pressed between 2 pieces of plastic and traced on clear
vinyl. The tracings were scanned into image files, and
analyzed for infarct size as a percent of the intact LV
using a custom Alpheion macro by T. DuFresne, Procter
& Gamble.
Osmotic minipump implantation
Between 7 (sham) and 10 (myocardial infarcted) rats per
treatment group were anesthetized with isoflurane and
Alza 28 day rat minipumps were implanted in the mid-
scapular region. A larger number of rats were included
in the myocardial infracted group since loss of rats due
to their congestive heart failure was anticipated. Pumps
were replaced every 28 days until the end of the study.
PG873637 was administered at a dose of 100 ug/kg/d.
Leg muscle function analysis
At the end of each of the studies, animals were anesthe-
tized using isoflurane, the right leg was shaved, and the
right extensor digitorum longus (EDL) and/or soleus
muscles exposed. Silk sutures were tied to the proximal
and distal tendons of the EDL and/or soleus muscles and
the EDL and/or soleus muscles were removed, tendon-
to-tendon. The muscles were placed into a plexiglass
chamber filled with Ringer solution (137 mM sodium
chloride, 24 mM sodium bicarbonate, 11 mM glucose,
5 mM potassium chloride, 1 mM magnesium sulfate,
1 mM sodium phosphate, 0.025 mM tubocurarine - all at
pH 7.4, constantly oxygenated with 95% oxygen/5% car-
bon dioxide) and maintained at 25°C. Muscle were
aligned horizontally between a servomotor lever arm and
a stainless steel fixed-post (Aurora Scientific Inc., model
6650LR) and field stimulated by pulses transmitted
between two platinum electrodes placed longitudinally
on either side of the muscle. Square wave pulses (0.2 ms
duration) generated by a personal computer with a Lab-
view board (Model PCI-MIO-16E-4, Labview Inc., Aus-
tin, TX, USA) were amplified (Acurus Power Amplifier
Model A250, Dobbs Ferry, NY, USA) to increase and sus-
tain current intensity to a sufficient level to produce a
maximum isometric tetanic contraction. Stimulation vol-
tage and muscle length (Lo) were adjusted to obtain max-
imum isometric twitch force. Maximum tetanic force
production (Po) was determined from the plateau of a
frequency-force relationship
Statistical analysis
Statistical analysis was performed using an ANCOVA
model with treatment effect and starting weight as the
covariates. Pair wise comparisons for all end-points
were generated using least-square means (SAS, Cary,
North Carolina), adjusted for unequal sample sizes and
starting weight.
Results
Aging rat model
Evaluation of muscle mass and Po following CRF2R agonist
treatment
Evaluation of absolute EDL muscle mass and force in 24,
25 and 27 month old female F344 rats did not show a sig-
nificant difference in absolute EDL mass with age but did
demonstrate a significant decrease in absolute force (Po)
at 27 months of age (13% decrease compared to 24
months of age) (Table 1). There were no statistically sig-
nificant aging-related differences in absolute soleus mus-
cle mass or Po (Table 1). An evaluation of aging related
differences in the relative EDL and soleus muscle mass
and Po demonstrated greater relative EDL and soleus
muscle mass with age; there were no differences in rela-
tive EDL Po with age while relative soleus Po was greater
at 25 months of age compared to 24 months of age but
this difference was not observed at 27 months of age.
T h ed i f f e r e n c ei nr e l a t i v em u s c l em a s s / P oc o m p a r e dt o
absolute muscle mass/Po is mainly driven by the decrease
in body mass observed with aging.
Evaluation of age-matched CRF2R agonist (PG873637)
treated versus vehicle treated rats resulted in greater abso-
lute EDL mass (+14%/+13%) and Po (+12%/+14%
p=0 . 0 6 )
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with 1 and 3 months of PG873637 treatment when
compared to the appropriate vehicle control (data
given as 1 month PG873637 over vehicle % increase/3
months PG873637 over vehicle % increase). Absolute
soleus mass was greater (+8%/+9%) although this dif-
ference was not statistically significant; absolute soleus
Po was greater (+9%/+13%) although only the 1 month
difference was statistically significant. Relative soleus
mass (+12%/+9%
p = 0.06) and Po (+14%/+15%
p = 0.06)
was greater with 1 and 3 months (respectively) of
PG873637 treatment when compared to the appropri-
ate vehicle control (Table 1).
Hamster emphysema model
EMP induction
As can be seen in Table 2, a large increase in lung
volume for both vehicle and PG873637 treated EMP
hamsters [EMP-vehicle (+141%) and EMP-PG873637
(+113%)] was observed relative to the vehicle and
PG873637 treated non-emphysemic control (Sham)
hamsters; lung volume-to-body weight ratios demon-
strated a similar change [EMP-vehicle (+136%) and
EMP-PG873637 (+154%)]. Lung volume was similar
within the EMP and Sham groups with and without
PG873637 treatment. Analysis of the heart indicated
that right ventricle weight was similar in both vehicle
and PG873637 treated EMP hamsters [EMP-vehicle
(+26%) and EMP-PG873637 (+46%)] when compared to
the vehicle and PG873637 treated Sham hamsters; RV
mass-to-body weight ratios demonstrated a similar dif-
ference [EMP-vehicle (+28%) and EMP-PG873637
(+67%)]. RV mass was similar within the EMP and
Sham groups with and without PG873637 treatment.
Evaluation of muscle mass and Po following CRF2R agonist
treatment
As can be seen in Table 2, absolute (+41%) and relative
(+31%) EDL mass was significantly greater in Sham-
PG873637 compared to Sham-vehicle animals while
only relative EDL mass was significantly greater (+15%)
in EMP-PG873637 compared to EMP-vehicle animals.
Absolute (+48%) and relative (+38%) EDL Po was signif-
icantly greater in Sham-PG873637 compared Sham-
vehicle animals. Absolute (+26%) and relative (+32%)
EDL Po was significantly greater in EMP-PG873637
compared to EMP-vehicle animals. There was no signifi-
cant difference in absolute and relative diaphragm mass
in PG873637 treated compared to vehicle treated Sham
animals. Relative (+12%) diaphragm mass was signifi-
cantly greater in PG873637 treated compared to vehicle
treated EMP animals.
Rat CHF model
CHF induction
As can be seen in Table 3, all rats with a myocardial
infarction demonstrate significant differences in frac-
tional area contractions (66% decrease MI vehicle versus
sham vehicle, 60% decrease MI PG873637 versus sham
PG873637); ejection fraction (63% decrease MI vehicle
versus sham vehicle, 58% decrease MI PG873637 versus
Table 1 Effects of 1 month or 3 months of treatment with either vehicle or PG873637 on female 24 month old F344
rat body mass, muscle mass, muscle absolute force (Po)
Time 0 1 month vehicle 1 month PG873637 3 month vehicle 3 month PG873637
Number of animals 8 8 7 14 16
Final body mass
(grams)
281.6
(8.1)
269.4
(5.0)
252.0#
(4.2)
256.9#
(6.7)
252.0#
(5.1)
EDL mass
(milligrams)
91.9
(1.0)
89.0
(1.9)
101.2*#
(2.1)
89.4
(1.5)
101.3*#
(4.2)
EDL mass/body mass
(milligram/gram)
0.33
(0.00)
0.34
(0.01)
0.40*#
(0.01)
0.35#
(0.01)
0.40*#
(0.01)
EDL Po
(milliNewtons)
2025.2
(18.7)
1965.6
(36.6)
2199.3*#
(59.3)
1761.4#
(56.3)
2004.6
(*p = 0.06)
(114.2)
EDL Po/body mass
(milliNewton/gram)
7.23
(0.09)
7.42
(0.11)
8.68*#
(0.30)
6.86
(0.19)
7.86*
(0.40)
Soleus mass
(milligrams)
79.8
(2.2)
82.6
(2.1)
89.0#
(3.2)
81.3
(2.0)
88.3
(4.0)
Soleus mass/body mass
(milligram/gram)
0.28
(0.01)
0.31#
(0.01)
0.35*#
(0.01)
0.32#
(0.01)
0.35
(*p = 0.06)#
(0.01)
Soleus Po
(milliNewtons)
1188.3
(24.6)
1244.5
(28.6)
1362.5*#
(45.3)
1128.1
(45.2)
1278.2
(81.3)
Soleus Po/body mass
(milliNewton/gram)
4.25
(0.08)
4.71#
(0.10)
5.37*#
(0.20)
4.39
(0.16)
5.03
(*p = 0.06)#
(0.29)
All data are given as the mean with the standard error of the mean in parenthesis. * - statistically significant difference (p < 0.05) versus the appropriate vehicle
control; # - statistically significant difference (p < 0.05) versus Time 0.
Hinkle et al. BMC Musculoskeletal Disorders 2011, 12:15
http://www.biomedcentral.com/1471-2474/12/15
Page 5 of 12sham PG873637); left ventricular systolic area (368%
increase MI vehicle versus sham vehicle, 305% increase
MI PG873637 versus sham PG873637); left ventricular
systolic volume (465% increase MI vehicle versus sham
vehicle, 447% increase MI PG873637 versus vehicle
PG873637); left ventricular diastolic area (118% increase
MI vehicle versus sham vehicle, 90% increase MI
PG873637 versus sham PG873637); left ventricular dia-
stolic volume (147% increase MI vehicle versus sham
vehicle, 118% increase MI PG873637 versus sham
PG873637); and lung weight (84% increase MI vehicle
versus sham vehicle, 50% increase MI PG873637 versus
sham PG873637) when compared to the appropriate
sham operated rats. All differences were consistent with
CHF including the greater lung weights. There were no
major differences between rats treated with vehicle or
the CRF2R agonist, PG873637, in any of the cardiac
parameters.
Evaluation of muscle mass and Po following CRF2R agonist
treatment
Results of the analysis of EDL and soleus muscle mass
and Po in sham and CHF rats treated with either vehicle
or PG873637 are shown in Table 3. Analysis of the EDL
muscle did not demonstrate a significant difference in
either absolute or relative mass between the sham and
MI vehicle treated rats; a statistically significant greater
absolute and relative EDL mass was observed in both
the sham (20% increase in absolute mass and 15%
increase in relative mass) and MI (20% increase in abso-
lute mass and 18% increase in relative mass) rats treated
with PG873637 when compared to the appropriate vehi-
cle control. Analysis of absolute and relative EDL mus-
cle Po demonstrated a statistically significant lower Po
in MI vehicle treated rats when compared to sham vehi-
cle treated rats; absolute and relative EDL Po was signif-
icantly greater with PG873637 treatment in both sham
(17% increase in absolute Po and 13% increase in rela-
tive Po) and MI (28% increase in absolute Po and 27%
increase in relative Po) rats when compared to vehicle
treatment. Analysis of absolute and relative soleus mus-
cle mass demonstrated no difference between MI and
sham vehicle treated animals; absolute and relative
soleus mass was greater with PG873637 treatment in
both sham (18% increase in absolute mass and 15%
increase in relative mass) and MI (13% increase in abso-
lute mass and 10% increase in relative mass) animals
when compared to vehicle control. Analysis of absolute
and relative soleus Po demonstrated a significantly
greater absolute Po in MI vehicle treated rats compared
to sham vehicle treated rats; treatment with PG873637
resulted in a significantly greater absolute and relative
sham (19% increase in absolute Po and 14% increase in
Table 2 Effect of 5 months of treatment with either vehicle or PG873637 on female sham or emphysemic (EMP)
hamster final body mass, lung volume, right ventricular (RV) mass, muscle mass and muscle absolute force (Po)
Sham vehicle Sham PG873637 EMP vehicle EMP PG873637
Number of animals 6 6 9 11
Final body mass (grams) 148.7
(7.6)
162.3
(9.0)
149.8
(4.1)
142.2
(4.4)
Lung volume
(milliliter)
2.3
(0.2)
2.4
(0.2)
5.4#
(0.4)
5.2#
(0.6)
Lung volume/body mass
(milliliter/gram)
0.02
(0.00)
0.02
(0.00)
0.04#
(0.00)
0.04#
(0.01)
RV mass
(milligrams)
115.7
(4.1)
109.6
(4.0)
145.5#
(6.3)
159.7#
(9.7)
RV mass/body mass
(milligram/gram)
0.78
(0.06)
0.69
(0.02)
0.99#
(0.06)
1.15#
(0.08)
EDL mass
(milligrams)
32.6
(2.2)
46.0*
(3.8)
33.0
(1.5)
35.7
(1.4)
EDL mass/body mass
(milligram/gram)
0.22
(0.01)
0.28*
(0.02)
0.22
(0.01)
0.25*
(0.01)
EDL Po
(milliNewtons)
832.5
(45.1)
1229.2*
(36.1)
837.6
(29.0)
1057.2*
(40.8)
EDL Po/body mass
(milliNewtons/gram)
5.57
(0.19)
7.70*
(0.35)
5.63
(0.13)
7.44*
(0.14)
Costal diaphragm mass
(milligrams)
252.2
(15.8)
290.5
(16.8)
242.9
(5.8)
260.9
(10.6)
Costal diaphragm mass/body mass
(milligrams/grams)
1.70
(0.09)
1.80
(0.05)
1.64
(0.03)
1.84*
(0.04)
All data are given as the mean with the standard error of the mean in parenthesis. * - statistically significant difference (p < 0.05) versus the appropriate vehicle
control; # - statistically significant difference (p < 0.05) versus control animals (non-emphysemic).
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12% increase in relative Po) soleus muscle Po compared
to vehicle treated rats.
Discussion
In this report we demonstrate for the first time that
long term treatment with a CRF2R agonist maintains
skeletal muscle mass and force production in animals
with chronic disease (emphysematous hamsters and rats
with CHF) and in aged rats.
Aging Rat Model
Previously, we demonstrated that activation of the
CRF2R can increase skeletal muscle mass and force
production in young mice and rats [46-48]. In the pre-
sent report we demonstrate that old rats, like young
rats, respond to pharmacological activation of the
CRF2R with greater absolute and/or relative skeletal
muscle mass and force production when compared to
age matched untreated rats. Thus, CRF2R functionality
is maintained throughout the aging process. Interest-
ingly, we observed that the aging-related loss of muscle
mass and force was greater in the EDL muscle (predo-
minantly Type II, fast twitch) than in the soleus muscle
(predominantly Type I, slow twitch). This is similar to
what has been observed by others [12,55,56]. The pre-
servation of both Type I and Type II muscle CRF2R
functionality in aged muscle indicates that in an aging
Table 3 Effects of three months of treatment with either vehicle or PG873637 on sham operated or myocardial
infracted rat body mass, fractional area contraction, ejection fraction, systolic area, systolic volume, diastolic area,
diastolic volume, scar weight, lung weight, muscle mass and muscle absolute force (Po).
Sham Vehicle 3 month Sham PG873637 3 month MI Vehicle 3 month MI PG873637 3 month
Number of animals 7 7 10 9
Final body mass
(grams)
482.8
(6.8)
476.8
(12.4)
480.5
(6.1)
487.4#
(7.6)
Final Fractional Area Contractions
(%)
63.4
(7.6)
65.2
(6.5)
21.7#
(6.9)
26.0#
(3.2)
Final Ejection Fraction
(%)
68.2
(8.6)
72.6
(4.9)
25.3#
(7.5)
30.5#
(3.6)
Final LV Systolic Area
(centimeters
2)
18.5
(4.1)
17.7
(3.8)
86.7#
(15.2)
71.8#
(13.1)
Final LV Systolic Volume
(milliliters)
0.2
(0.1)
0.2
(0.1)
1.3#
(0.3)
1.0#
(0.3)
Final LV Diastolic Area
(millimeters
2)
50.7
(5.0)
51.1
(5.2)
110.4#
(14.7)
97.3#
(18.5)
Final LV Diastolic Volume
(milliliters)
0.7
(0.1)
0.7
(0.1)
1.7#
(0.3)
1.5#
(0.3)
Final Scar Weight
(grams)
NA NA 0.1
(0.0)
0.1
(0.0)
Final Lung Weight
(grams)
1.5
(0.1)
1.5
(0.1)
2.8#
(0.9)
2.2#
(1.0)
EDL mass
(milligrams)
189.9
(3.7)
228.6*
(6.5)
191.0
(1.9)
230.0*
(5.8)
EDL mass/body mass
(milligram/gram)
0.41
(0.01)
0.47*
(0.01)
0.40
(0.01)
0.47*
(0.01)
EDL Po
(milliNewtons)
3348.7
(78.9)
3909.9*
(71.7)
3073.3#
(96.3)
3927.7*
(52.6)
EDL Po/body mass
(milliNewton/gram)
7.16
(0.13)
8.09*
(0.18)
6.41#
(0.24)
8.12*
(0.13)
Soleus mass
(milligrams)
188.9
(3.2)
222.4*
(7.9)
197.0
(2.6)
222.4*
(7.9)
Soleus mass/body mass
(milligram/gram)
0.40
(0.01)
0.46*
(0.01)
0.41
(0.01)
0.45*
(0.01)
Soleus Po
(milliNewtons)
2033.6
(26.9)
2420.9*
(88.1)
2177.5#
(46.0)
2444.7*
(68.8)
Soleus Po/body mass
(milliNewton/gram)
4.38
(0.08)
4.99*
(0.15)
4.53
(0.09)
5.06*
(0.14)
All data given with standard error of the mean in paranthesis. * - statistically significant (p < 0.05) versus appropriate vehicle control: # - statistically significant
(p < 0.05) versus appropriate sham control.
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Page 7 of 12associated physiological background, the CRF2R is func-
tional and capable of maintaining muscle mass.
Together, these data demonstrate that activation of the
CRF2R can maintain muscle mass and force production
and this is independent of aging associated physiological
dysfunction such as nutritional imbalance, cumulative
muscle damage, metabolic imbalance, alterations in hor-
mones/cytokines and loss of regenerative potential
[2-8],. A similar effect has been observed following
treatment of aged F344 rats with the b2-adrenergic ago-
n i s t ,f e n o t e r o l[ 1 2 ] .T h u s ,t r e a t m e n tw i t haC R F 2 Ra g o -
n i s tm a yb eu s e f u li nc o m b a t i n gt h em u s c l ew e a k n e s s
and frailty associated with aging.
Hamster emphysema model
The purpose of this investigation was to determine
whether the administration of a CRF2R selective agonist
would maintain skeletal mass and force in animals with
chronic EMP. The results of this investigation demon-
strate that 5 months of treatment of EMP animals with
a CRF2R selective agonist results in greater absolute and
relative EDL force when compared to vehicle treated
EMP animals. We did not see a difference in absolute
EDL or diaphragm muscle mass in emphysemic animals
treated with a CRF2R agonist when compared to vehicle
treated EMP animals, although relative EDL and dia-
phragm mass were greater when compared to vehicle
treated EMP animals.
Diaphragm atrophy
Similar to locomotory muscles the diaphragm is adapta-
ble. It is well established that the diaphragm can adapt
biochemically and structurally in response to alterations
in metabolic load secondary to lung hyperinflation
[24,28,33]. Specifically, EMP-induced increases in
respiratory muscle metabolic demands [57] result in ele-
vated oxidative enzyme capacity [24,28,33]. Moreover,
EMP-induced diaphragm capillary proliferation is
thought to be important for enhancing O2 diffusion and
extraction [25]. In addition, the diaphragm muscle fibers
shorten chronically which acts to re-establish a favorable
position on the diaphragm length-tension curve [24,25].
In contrast, reports on EMP-induced diaphragm fiber
cross-sectional changes are mixed. As discussed earlier,
diaphragm fiber hypertrophy, atrophy, or no change has
been reported in animal models of EMP. Respiratory
muscle weakness is well documented in COPD patients
and can lead to hypercapnia [23,58-61]. Thus, if respira-
tory muscle weakness contributes to chronic hypercap-
nia and ultimately increased mortality in COPD
patients, it is of the utmost importance to find therapeu-
tic interventions aimed at preventing this negative out-
come. In this investigation, we did not observe
significant changes in diaphragm muscle mass in EMP
animals although significant changes in lung and right
ventricles did occur. Nor did we observe significant
changes in EDL muscle mass or force production in
EMP animals compared to control animals. Importantly,
treatment with a CRF2R agonist resulted in a directional
increase in diaphragm muscle mass in both normal and
EMP animals and a significant increase in EDL force
production in normal and EMP animals. Interestingly,
EDL muscle mass increased with CRF2R agonist treat-
ment in normal animals but not in EMP animals. At
present we do not understand the significance of the
disconnect between EDL mass and force in EMP ani-
mals but future studies will focus on understanding this
observation.
Mechanical ventilation
Acute respiratory failure (ARF) in COPD patients is a
common cause of hospital admissions [62]. Mechanical
ventilation (MV) is often administered if conservative
treatment fails [63,64]. However, mortality rates rise
from 10% for conservative treatment up to 50% if MV is
required [65]. Moreover, weaning from MV is clinically
challenging, with up to 67% failure rate in COPD
patients with respiratory muscle weakness and/or dys-
function [66-69]. Those patients that do survive spend a
longer time weaning in comparison to most other
pathological conditions [70]. Extubation failure from
MV occurs in other conditions, with up to 20% of all
patients on prolonged MV experience weaning difficul-
ties [71]. Although the mechanisms for these difficulties
are not fully understood, respiratory muscle dysfunction
contributes to this problem [72,73]. Indeed, diaphragm
fatigue has been demonstrated as a major factor affect-
ing weaning failure [74,75]. For example, Le Bourdelles
et al. demonstrated that mechanically-ventilated animals
have reductions in diaphragm isometric force and mass
[76]. Furthermore, Powers and coworkers have extended
this work by demonstrating prolonged MV promotes
increased diaphragm protein degradation, reduced pro-
tein synthesis, increased oxidative stress, and impair-
ment of antioxidant defenses [72,77,78]. Therefore,
conservation of respiratory muscle mass may reduce
MV treatment length and weaning difficulties. The
results of this investigation provide suggestive evidence
that CRF2R agonist may increase diaphragm muscle
mass. This together with the observation that treatment
w i t haC R F 2 Ra g o n i s ti se f f e c t i v ei np r e v e n t i n gl o s so f
non-actively contracting skeletal muscle [46,48] suggest
that treatment with a CRF2R agonist may be an impor-
tant therapeutic intervention for ameliorating the dele-
terious effects of MV on diaphragm mass and function.
More work will be needed before we fully understand
the potential of CRF2R agonist in treating MV weaning
failure.
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In this report we have evaluated the effect of CRF2R
agonist treatment on skeletal muscle mass and function
in rats with ongoing CHF. Treatment with a CRF2R
agonist resulted in greater EDL (fast twitch) and soleus
(slow twitch) absolute and relative skeletal muscle mass
and force production in rats with and without chronic
CHF when compared to the appropriate vehicle treated
animals. Interestingly, the EDL muscle demonstrated
lower absolute force production in CHF rats when com-
pared to sham rats without a significant difference in
mass; no difference in absolute force production or
mass was observed in the soleus muscle from CHF rats.
Even with this deficit in EDL function, the CRF2R
mediated difference in mass and force production was
similar in both normal and CHF rats when compared to
vehicle treated normal and CHF rats, indicating that
CRF2R functionality was not compromised by the
changes that cause a loss in force. The observation that
oxidative muscles are more resistant than glycolytic
m u s c l e st ol o s so ff u n c t i o ni nC H Fh a sb e e no b s e r v e d
previously in mice [79,80]. In addition, the loss of skele-
tal muscle force but not mass has been described pre-
viously both in animals and humans with CHF, although
there is model and species specificity in the type of
muscle fiber that is affected [44].
CHF results in major physiological dysfunction at both
the organismal and tissue levels including cardiac
cachexia. These changes are believed to result from
decreased tissue oxygenation and increased levels of
stress hormones and cytokines including TNF-a,I L - 6
and cortisol [34-36]. Even though these catabolic cyto-
kines/hormones are present, activation of the CRF2R in
CHF rats resulted in increased muscle mass and force
production, indicating that the CRF2R pathway is able
to override these catabolic signals. Thus, treating CHF
patients with a CRF2R agonist may be a useful thera-
peutic option to improve strength and muscle function
in patients suffering from cardiac cachexia.
Overall Significance
Together the findings described in this report provide
support for the concept that pharmacological activation
of the CRF2R may prove useful in improving muscle
function in individuals experiencing weakness associated
with chronic disorders and aging. The most consistent
finding amongst all three models is the observation that
CRF2R agonist treatment results in greater muscle force
production compared to vehicle treatment. The change
in force production observed with CRF2R agonist treat-
ment was often, but not always, associated with a
change in muscle mass - the exception being emphyse-
mic hamsters (although when the change in muscle
mass is normalized to body mass a significant change is
observed). The reason for this discontinuity is at present
unclear since in our previous investigations of acute and
chronic atrophy (cancer cachexia and disuse atrophy),
we consistently observed parallel increases in absolute
muscle mass and force production following CRF2R
activation [46-51]. Additional work is necessary to deter-
mine if this exception is significant or an experimental
artifact.
An interesting observation from this work is that even
though skeletal muscle weights were increased following
CRF2R activation, increases in absolute body mass were
not consistently observed. This is puzzling since skeletal
muscle accounts for a significant portion of absolute
body mass. This inconsistency can be explained by the
known effects of CRF2R activation on another major
component of absolute body mass, adipose tissue.
Recent reports have shown that the CRF2R has a major
role, via both central and peripheral action, in modulat-
ing body mass [81-84]. Importantly for this report, it
has been observed that peripherally administered CRF2R
agonists both increases skeletal muscle mass as well as
decreases adipose tissue mass in normal rats [81], most
likely by direct activation of CRF2Rs in skeletal muscle
and adipose tissue. Thus, the net effect of CRF2R activa-
tion on absolute body mass depends on the relative
amounts of skeletal muscle and adipose tissue in an ani-
mal. We have observed that when skeletal muscle makes
a greater contribution to absolute body mass than adi-
pose tissue (such as in lean young animals), CRF2R acti-
vation results in an increase in body mass; we have also
observed a decrease in body mass following CRF2R acti-
vation when the adipose tissue content of an animal is
high (obese animals) and the resulting loss of adipose
tissue mass more than offsets the gain in skeletal muscle
mass (RJI, unpublished observations).
Finally, we believe the most significant aspect of this
work is the observed robustness of the effect of CRF2R
activation on skeletal muscle mass and force production.
The findings in this study, when combined with our
previous findings, demonstrate that activation of the
CRF2R results in greater skeletal muscle mass and force
production compared to vehicle treatment and that the
CRF2R mediated changes are independent of specie,
physiological condition, treatment length and dosing
paradigm [46-51]. In addition, the observation that
chronic administration of a CRF2R agonist maintains
muscle mass and force production during the entire
treatment period demonstrates that down regulation of
the CRF2R does not occur with continuous stimulation.
This provides evidence that chronic administration of a
CRF2R agonist will result in long term maintenance of
muscle function in patients suffering from chronic dis-
ease. Collectively, these studies provide the rationale for
considering CRF2R agonists as potential therapeutics for
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Page 9 of 12the treatment of both acute and chronic muscle wasting
disorders in humans.
Conclusion
We found that treatment of aged animals and animals
with a chronic disease with a CRF2R agonist resulted in
maintenance of skeletal muscle mass and force produc-
tion when compared to vehicle treatment.
Author details
1Research Division, Procter & Gamble Company, Mason, OH, USA.
2Department of Health and Exercise Science, Gustavus Adolphus College, St.
Peter, MN, USA.
3Departments of Kinesiology and Anatomy & Physiology,
Kansas State University, Manhattan, KS, USA.
Authors’ contributions
All authors made substantial intellectual, design and/or executional
contributions to this study as follows: RTH provided intellectual, design and
executional contributions; FRL provided executional contributions; ETD
provided executional contributions; DLR provided executional contributions;
JMZ provided design and executional contributions; TPO provided
intellectual and design contributions; KGM provided executional
contributions; JPM provided intellectual, design and executional
contributions; LFF provided executional contributions; TIM provided
intellectual and design contributions; DCP provided intellectual and design
contributions; and RJI provided intellectual, design and executional
contributions. All authors gave final approval of the manuscript.
Competing interests
This work was supported by the Procter & Gamble Company. RTH, FRL, ETD,
DLR, JMZ, TPO, KGM and RJI are or were at the time these studies were
performed employees of the Procter & Gamble Company.
Received: 21 December 2009 Accepted: 14 January 2011
Published: 14 January 2011
References
1. Baumgartner RN: Body composition in healthy aging. Ann NY Acad Sci
2000, 904:437-448.
2. Greenlund LJS, Nair KS: Sarcopenia - consequences, mechanisms, and
potential therapies. Mech Ageing Dev 2003, 124:287-299.
3. Marcell TJ: Sarcopenia: causes, consequences, and preventions. J Gerontol
2003, 10:911-916.
4. Melton LJ, Khosla S, Riggs BL: Epidemiology of sarcopenia. Mayo Clin Proc
2000, 75:S10-S13.
5. Roubenoff R: Sarcopenia and its implications for the elderly. Eur J Clin
Nutr 2000, 54:S40-S47.
6. VanItallie TB: Frailty in the elderly: contributions of sarcopenia and
visceral protein depletion. Metabolism 2003, 52:22-26.
7. Waters DL, Baumgartner RN, Garry PJ: Sarcopenia: current perspectives. J
Nutr Health Aging 2000, 4:133-139.
8. Zinna EM, Yarasheski KE: Exercise treatment to counteract protein
wasting of chronic diseases. Curr Opin Clin Nutr Metab Care 2003, 6:87-93.
9. Cai DQ, Li M, Lee KKH, Lee KM, Qin L, Chan KM: Parvalbumin expression is
downregulated in rat fast twitch skeletal muscles during aging. Arch
Biochem Biophys 2001, 387:202-208.
10. Chen KD, Alway SE: Clenbuterol reduces soleus muscle fatigue during
disuse in aged rats. Muscle Nerve 2001, 24:211-222.
11. Hepple RT, Ross KD, Rempfer AB: Fiber atrophy and hypertrophy in
skeletal muscles of late middle-aged Fischer 344 x Brown Norway F1-
hybrid rats. J Gerontol 2004, 59A:108-117.
12. Ryall JG, Plant DR, Gregorevic P, Sillence MN, Lynch GS: B2-agonist
administration reverses muscle wasting and improves muscle function
in aged rats. J Physiol 2003, 555.1:175-188.
13. Schertzer JD, Plant DR, Ryall JG, Beitzel F, Stupka N, Lynch GS: Beta2-
agonist administration increases sarcoplasmic reticulum Ca2+-ATPase
activity in aged rat skeletal muscle. Am J Physiol Endocrinol Metab 2005,
288:E526-E533.
14. Smith WN, Dirks A, Sugiura T, Muller S, Scarpace P, Powers SK: Alteration of
contractile force and mass in the senescent diaphragm with B2-agonist
treatment. J Appl Physiol 2002, 92:941-948.
15. Wineski LE, von Deutsch DA, Abukhalaf IK, Pitts SA, Potter DE, Paulsen DF:
Muscle-specific effects of hindlimb suspension and clenbuterol in
mature male rats. Cells Tissue Organs 2002, 171:188-198.
16. Carter CS, Cesari M, Ambrosius WT, Hu N, Diz D, Oden S, Sonntag WE,
Pahor M: Angiotensin-converting enzyme inhibition, body composition
and physical performance in aged rats. J Gerontol 2004, 59A:416-423.
17. Carter WJ, Lynch ME: Comparison of the effects of salbutamol and
clenbuterol on skeletal muscle mass and carcass composition in
senescent rats. Metabol 1994, 43:1119-1125.
18. Larkin LM, Horwitz BA, Eiffert KC, McDonald RB: Adrenergic stimulated
skeletal muscle glycogenolysis in perfused hindlimbs of young and old
male Fischer 344 rats. Am J Physiol 1994, 266:R749-R755.
19. Mazzeo RS, Podolin DA, Henry V: Effects of age and endurance training
on beta-adrenergic receptor characteristics in Fischer 344 rats. Mech
Ageing Dev 1995, 84:157-169.
20. Burrows B, Earle RH: Prediction of survival in patients with chronic airway
obstruction. Am Rev Respir Dis 1969, 99:865-871.
21. Renzetti AD Jr, McClement JH, Litt BD: The Veterans Administration
cooperative study of pulmonary function. 3. Mortality in relation to
respiratory function in chronic obstructive pulmonary disease. Am J Med
1966, 41:115-129.
22. Roussos C: Function and fatigue of respiratory muscles. Chest 1985,
88:124S-132S.
23. Sliwinski P, Macklem PT: Inspiratory muscle dysfunction as a cause of
death in COPD patients. Monaldi Arch Chest Dis 1997, 52:380-383.
24. Farkas GA, Roussos C: Histochemical and biochemical correlates of
ventilatory muscle fatigue in emphysematous hamsters. J Clin Invest
1984, 74:1214-1220.
25. Poole DC, Mathieu-Costello O: Effect of pulmonary emphysema on
diaphragm capillary geometry. J Appl Physiol 1997, 82:599-606.
26. Kelsen SG, Wolanski T, Supinski GS, Roessmann U: The effect of elastase-
induced emphysema on diaphragmatic muscle structure in hamsters.
Am Rev Respir Dis 1983, 127:330-334.
27. Mattson JP, Delp MD, Poole DC: Differential effects of emphysema on
skeletal muscle fibre atrophy in hamsters. Eur Respir J 2004, 23:703-707.
28. Lewis MI, Zhan WZ, Sieck GC: Adaptations of the diaphragm in
emphysema. J Appl Physiol 1992, 72:934-943.
29. Doucet M, Debigare R, Joanisse DR, Cote C, Leblanc P, Gregoire J,
Deslauriers J, Vaillancourt R, Maltais F: Adaptation of the diaphragm and
the vastus lateralis in mild-to-moderate COPD. Eur Respir J 2004,
24:971-979.
30. Mattson JP, Poole DC: Pulmonary emphysema decreases hamster skeletal
muscle oxidative enzyme capacity. J Appl Physiol 1998, 85:210-214.
31. Mattson JP, Poole DC, Hahn SA, Musch TI, Hinkle RT, Isfort RJ: Maximal
force is unaffected by emphysema-induced atrophy in extensor
digitorum longus. Respir Physiol Neurobiol 2008, 161:119-124.
32. Mattson JP, Martin JC: Emphysema-induced reductions in locomotory
skeletal muscle contractile function. Exp Physiol 2005, 90:519-525.
33. Zhang XL, Pang BS, Hou XL, Wang J, Wang C: Oxidative stress and
peripheral skeletal muscle dysfunction in rats with emphysema. Chin
Med J 2010, 123:40-44.
34. Anker SD, Coats AJS: Cardiac Cachexia. A syndrome with impaired
survival and immune and neuroendocrine activation. Chest 1999,
115:836-847.
35. Anker SD, Ponikowski PP, Clark AL, Leyva F, Rauchhaus M, Kemp M,
Teixeira MM, Hellewell PG, Hooper J, Poole-Wilson PA, Coats AJS: Cytokines
and neurohormones relating to body composition alterations in the
wasting syndrome of chronic heart failure. Eur Heart J 1999, 20:683-693.
36. Janssen SPM, Gayan-Ramirez G, Van Den Bergh A, Herijgers P, Maes K,
Verbeken E, Decramer M: Interleukin-6 causes myocardial failure and
skeletal muscle atrophy in rats. Circulation 2005, 111:996-1005.
37. Libera LD, Ravara B, Angelini A, Rossini K, Sandri M, Thiene G, Ambrosio GB,
Vescovo G: Beneficial effects on skeletal muscle of the angiotensin II
type 1 receptor blocker Irbesartan in experimental heart failure.
Circulation 2001, 103:2195-2200.
Hinkle et al. BMC Musculoskeletal Disorders 2011, 12:15
http://www.biomedcentral.com/1471-2474/12/15
Page 10 of 1238. Nagaya N, Uematsu M, Kojima M, Ikeda Y, Yoshihara F, Shimizu W,
Hosoda H, Hirota Y, Ishida H, Mori H, Kangawa K: Chronic administration
of ghrelin improves left ventricular dysfunction and attenuates
development of cardiac cachexia in rats with heart failure. Circulation
2001, 104:1430-1435.
39. Xu XB, Pang JJ, Cao JM, Ni C, Xu RK, Peng XZ, Yu XX, Guo S, Chen MC,
Chen C: GH-releasing peptides improve cardiac dysfunction and
cachexia dn suppress stress-related hormones and cardiomyocyte
apoptosis in rats with heart failure. Am J Physiol Heart Circ Physiol 2005,
289:1643-1651.
40. Carvalho RF, Cicogna AC, Campos GE, De Assis JM, Padovani CR, Okashi MP,
Pai-Silva MD: Myosin heavy chain expression and atrophy in rat skeletal
muscle during transition from cardiac hypertrophy to heart failure. Int J
Exp Pathol 2003, 84:201-206.
41. Carvalho RF, Cicogna AC, Campos GE, Lopes Fda S, Sugizaki MM,
Nogueira CR, Pai-Silva MD: Heart failure alters MyoD and MRF4
expression in rat skeletal muscle. Int J Exp Pathol 2006, 87:219-225.
42. Delp MD, Duan C, Mattson JP, Musch TI: Changes in skeletal muscle
biochemistry and histology relative to fiber type in rats with heart
failure. J Appl Physiol 1997, 83:1291-1299.
43. Lunde PK, Dahlstedt AJ, Bruton JD, Lannergren J, Thoren P, Sejersted OM,
Westerblad H: Contraction and intracellular Ca2+ handling in isolated
skeletal muscle of rats with congestive heart failure. Circ Res 2001,
88:1299-1305.
44. Lunde PK, Verburg E, Eriksen M, Sejersted OM: Contractile properties of in
situ perfused skeletal muscle from rats with congestive heart failure. J
Physiol 2002, 540.2:571-580.
45. Simonini A, Long CS, Dudley GA, Yue P, McElhinny J, Massie BM: Heart
failure in rats causes changes in skeletal muscle morphology and gene
expression that are not explained by reduced activity. Circ Res 1996,
79:128-136.
46. Hinkle RT, Donnelly E, Cody DB, Bauer MB, Isfort RJ: Urocortin II treatment
reduces skeletal muscle mass and function loss during atrophy and
increases nonatrophying skeletal muscle mass and function.
Endocrinology 2003, 144:4939-4946.
47. Hinkle RT, Donnelly E, Cody DB, Bauer MB, Sheldon RJ, Isfort RJ:
Corticotropin releasing factor 2 receptor agonists reduce the
denervation-induced loss of rat skeletal muscle mass and force and
increase non-atrophying skeletal muscle mass and force. J Muscle Res Cell
Motil 2005, 25:539-547.
48. Hinkle RT, Donnelly E, Cody DB, Samuelsson S, Lange JS, Bauer MB,
Tarnopolsky M, Sheldon RJ, Coste SC, Tobar E, Stenzel-Poore MP, Isfort RJ:
Activation of the CRF2 receptor modulates skeletal muscle mass under
physiological and pathological conditions. Am J Physiol Endocrinol Metab
2003, 285:E889-E898.
49. Hall JE, Kaczor JJ, Hettinga BP, Isfort RJ, Tarnopolsky MA: Effects of a CRF2R
agonist and exercise on mdx and wildtype skeletal muscle. Muscle Nerve
2007, 36:336-341.
50. Hinkle RT, Lefever FR, Dolan ET, Reichart DL, Dietrich JA, Gropp KE,
Thacker RI, Demuth JP, Stevens PJ, Qu XA, Varbanov AR, Wang F, Isfort RJ:
Corticotrophin releasing factor 2 receptor agonist treatment significantly
slows disease progression in mdx mice. BMC Med 2007, 5:18.
51. Argiles JM, Figueras M, Ametller E, Fuster G, Olivan M, de Oliveira CC,
Lopez-Soriano FJ, Isfort RJ, Busquets S: Effects of CRF2R agonist on tumor
growth and cachexia in mice implanted with Lewis lung carcinoma
cells. Muscle Nerve 2008, 37:190-195.
52. Mazur AW, Wang F, Tscheiner M, Donnelly E, Isfort RJ: Sauvagine analogs
selective for corticotropin releasing factor 2 receptor: effects of
substitutions at positions 35 and 39 on CRFR selectivity. Peptides 2005,
26:887-891.
53. Scherle W: A simple method for volumetry of organs in quantitative
stereology. Mikroskopie 1970, 26:57-60.
54. Musch TI, Terrell JA: Skeletal muscle blood flow abnormalities in rats with
a chronic myocardial infarction: rest and exercise. Am J Physiol 1992, 262:
H411-H419.
55. Balagopal P, Schimke JC, Ades P, Adey D, Nair KS: Age effect on transcript
levels and synthesis rate of muscle MHC and response to resistance
exercise. Am J Physiol Endocrinol Metab 2001, 280:E203-E208.
56. McKiernan S, Bua E, McGorray J, Aiken J: Early-onset calorie restriction
conserves fiber number in aging rat skeletal muscle. FASEB J 2004,
18:580-581.
57. Cherniack RM: The oxygen consumption and efficiency of the respiratory
muscles in health and emphysema. J Clin Invest 1959, 38:494-499.
58. Gosselink R, Troosters T, Decramer M: Distribution of muscle weakness in
patients with stable chronic obstructive pulmonary disease. J Cardiopulm
Rehabil 2000, 20:353-360.
59. Ishikawa S, Hayes JA: Functional morphotometry of the diaphragm in
patients with chronic obstructive lung disease. Am Rev Respir Dis 1973,
108:135-138.
60. Rochester DF, Braun NM: Determinants of maximal inspiratory pressure in
chronic obstructive pulmonary disease. Am Rev Respir Dis 1985, 132:42-47.
61. Scott KW, Hoy J: The cross sectional area of diaphragmatic muscle fibres
in emphysema, measured by an automated image analysis system. J
Pathol 1976, 120:121-128.
62. Jayananda D: Medical intensive care, Chulalongkorn Hospital. Indications,
interventions and outcomes. Chula Med J 1988, 32:155-164.
63. Brochard L, Mancebo J, Wysocki M, Lofaso F, Conti G, Rauss A,
Simonneau G, Benito S, Gasparetto A, Lemaire F, Isabey D, Harf A:
Noninvasive ventilation for acute exacerbations of chronic obstructive
pulmonary disease. N Engl J Med 1995, 333:817-822.
64. Plant PK, Owen JL, Elliott MW: Early use of non-invasive ventilation for
acute exacerbations of chronic obstructive pulmonary disease on
general respiratory wards: a multicentre randomised controlled trial.
Lancet 2000, 355:1931-1935.
65. Limthongkul S, Wongthim S, Udompanich V, Charoenlap P,
Nuchprayoon CJ: Mechanical and non-mechanical ventilation of
respiratory failure in chronic obstructive pulmonary disease. J Med Assoc
Thai 1993, 76:1-8.
66. Conti G, De Blasi R, Pelaia P, Benito S, Rocco M, Antonelli M, Bufi M,
Mattia C, Gasparetto A: Early prediction of successful weaning during
pressure support ventilation in chronic obstructive pulmonary disease
patients. Crit Care Med 1992, 20:366-371.
67. Nava S, Rubini F, Zanotti E, Ambrosino N, Bruschi C, Vitacca M, Fracchia C,
Rampulla C: Survival and prediction of successful ventilator weaning in
COPD patients requiring mechanical ventilation for more than 21 days.
Eur Respir J 1994, 7:1645-1652.
68. Pourriat JL, Lamberto C, Hoang PH, Fournier JL, Vasseur B: Diaphragmatic
fatigue and breathing pattern during weaning from mechanical
ventilation in COPD patients. Chest 1986, 90:703-707.
69. Robriquet L, Georges H, Leroy O, Devos P, D’escrivan T, Guery B: Predictors
of extubation failure in patients with chronic obstructive pulmonary
disease. J Crit Care 2006, 21:185-190.
70. Esteban A, Alia I, Ibanez J, Benito S, Tobin MJ: Modes of mechanical
ventilation and weaning. A national survey of Spanish hospitals. The
Spanish Lung Failure Collaborative Group. Chest 1994, 106:1188-1193.
71. Lemaire F: Difficult weaning. Intensive Care Med 1993, 19:S69-S73.
72. Powers SK, Shanely RA, Coombes JS, Koesterer TJ, McKenzie M, Van
Gammeren D, Cicale M, Dodd SL: Mechanical ventilation results in
progressive contractile dysfunction in the diaphragm. J Appl Physiol 2002,
92:1851-1858.
73. Tobin MJ, Laghi F, Jubran A: Respiratory muscle dysfunction in
mechanically-ventilated patients. Mol Cell Biochem 1998, 179:87-98.
74. Murciano D, Boczkowski J, Lecocguic Y, Emili JM, Pariente R, Aubier M:
Tracheal occlusion pressure: a simple index to monitor respiratory
muscle fatigue during acute respiratory failure in patients with chronic
obstructive pulmonary disease. Ann Intern Med 1988, 108:800-805.
75. Yanos J, Wood LD, Davis K, Keamy M: The effect of respiratory and lactic
acidosis on diaphragm function. Am Rev Respir Dis 1993, 147:616-619.
76. Le Bourdelles G, Viires N, Boczkowski J, Seta N, Pavlovic D, Aubier M: Effects
of mechanical ventilation on diaphragmatic contractile properties in
rats. Am J Respir Crit Care Med 1994, 149:1539-1544.
77. Shanely RA, Zergeroglu MA, Lennon SL, Sugiura T, Yimlamai T, Enns D,
Belcastro A, Powers SK: Mechanical ventilation-induced diaphragmatic
atrophy is associated with oxidative injury and increased proteolytic
activity. Am J Respir Crit Care Med 2002, 166:1369-1374.
78. Shanely RA, Van Gammeren D, Deruisseau KC, Zergeroglu AM,
McKenzie MJ, Yarasheski KE, Powers SK: Mechanical ventilation depresses
protein synthesis in the rat diaphragm. Am J Respir Crit Care Med 2004,
170:994-999.
79. Li P, Waters RE, Redfern SI, Zhang M, Mao L, Annex BH, Yan Z: Oxidative
phenotype protects myofibers from pathological insults induced by
chronic heart failure in mice. Am J Pathol 2007, 170:599-608.
Hinkle et al. BMC Musculoskeletal Disorders 2011, 12:15
http://www.biomedcentral.com/1471-2474/12/15
Page 11 of 1280. Yu Z, Ping L, Zhang M, Hannink M, Stamler JS, Zhen Y: Fiber type-specific
nitric oxide protects oxidative myofibers against cachectic stimuli. PLOS
One 2008, 3:1-10.
81. Argiles JM, Fontes-Oliveria CC, Fuster G, Ametller E, Figueras M, Olivan M,
Lopez-Soriano FJ, Qu X, Demuth J, Stevens P, Varbanov A, Wang F, Isfort RJ,
Busquets S: Patterns of gene expression in muscle and fat in tumour-
bearing rats: effects of CRF2R agonist on cachexia. Muscle Nerve 2010,
42:936-949.
82. Seres J, Bornstein SR, Seres P, Willenberg HS, Schulte KM, Scherbaum WA,
Ehrhart-Bornstein M: Corticotropin-releasing hormone system in human
adipose tissue. J Clin Endo Metab 2004, 89:965-970.
83. Carlin KM, Vale WW, Bale TL: Vital functions of corticotrophin-releasing
factor (CRF) pathways in maintenance and regulation of energy
homeostasis. Proc Natl Acad Sci USA 2006, 103:3462-3467.
84. Cottone P, Sabino V, Nagy TR, Coscina DV, Zorrilla EP: Feeding
microstructure in diet-induced obesity susceptible versus resistant rats:
central effects of urocortin 2. J Physiol 2007, 583.2:487-504.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2474/12/15/prepub
doi:10.1186/1471-2474-12-15
Cite this article as: Hinkle et al.: Treatment with a corticotrophin
releasing factor 2 receptor agonist modulates skeletal muscle mass and
force production in aged and chronically ill animals. BMC Musculoskeletal
Disorders 2011 12:15.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hinkle et al. BMC Musculoskeletal Disorders 2011, 12:15
http://www.biomedcentral.com/1471-2474/12/15
Page 12 of 12